• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study.

作者信息

Fuchs Charles S, Marshall John, Barrueco José

出版信息

J Clin Oncol. 2008 Feb 1;26(4):689-90. doi: 10.1200/JCO.2007.15.5390.

DOI:10.1200/JCO.2007.15.5390
PMID:18235136
Abstract
摘要

相似文献

1
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study.伊立替康联合持续静脉输注、大剂量推注或口服氟嘧啶用于转移性结直肠癌一线治疗的随机对照试验：BICC-C研究的更新结果
J Clin Oncol. 2008 Feb 1;26(4):689-90. doi: 10.1200/JCO.2007.15.5390.
2
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.改良 XELIRI（卡培他滨联合伊立替康）对比 FOLFIRI（亚叶酸钙、氟尿嘧啶、伊立替康），二者均联合或不联合贝伐珠单抗，作为转移性结直肠癌的二线治疗（AXEPT）：一项多中心、开放标签、随机、非劣效性、3 期临床试验。
Lancet Oncol. 2018 May;19(5):660-671. doi: 10.1016/S1470-2045(18)30140-2. Epub 2018 Mar 16.
3
Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).贝伐珠单抗联合方案治疗既往未治疗的转移性结直肠癌患者的疗效和安全性：贝伐珠单抗联合 5-氟尿嘧啶、亚叶酸钙加伊立替康与贝伐珠单抗联合卡培他滨加伊立替康随机 II 期研究的最终结果（FNCLCC ACCORD 13/0503 研究）。
Eur J Cancer. 2013 Apr;49(6):1236-45. doi: 10.1016/j.ejca.2012.12.011. Epub 2013 Jan 24.
4
Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study.比较一线伊立替康/氟嘧啶联合方案在老年与非老年转移性结直肠癌患者中的安全性和疗效：推注、输注或卡培他滨联合喜得康-塞来昔布研究的结果
Cancer. 2009 Jun 15;115(12):2617-29. doi: 10.1002/cncr.24305.
5
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.伊立替康联合持续静脉输注、大剂量推注或口服氟嘧啶用于转移性结直肠癌一线治疗的随机对照试验：BICC-C研究结果
J Clin Oncol. 2007 Oct 20;25(30):4779-86. doi: 10.1200/JCO.2007.11.3357.
6
Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.西妥昔单抗联合XELIRI或XELOX用于转移性结直肠癌的一线治疗。
Clin Colorectal Cancer. 2008 Mar;7(2):110-7. doi: 10.3816/CCC.2008.n.015.
7
[Metastatic colorectal cancer: adjournments from ESMO 2006].[转移性结直肠癌：2006年欧洲肿瘤内科学会会议延期内容]
Tumori. 2006 Nov-Dec;92(6):1-12. doi: 10.1177/030089160609200627.
8
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.贝伐珠单抗联合 FOLFOX、XELOX、FOLFIRI 和氟嘧啶类药物一线治疗转移性结直肠癌的安全性和有效性：BEAT 研究。
Ann Oncol. 2009 Nov;20(11):1842-7. doi: 10.1093/annonc/mdp233. Epub 2009 Apr 30.
9
Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer.贝伐珠单抗联合卡培他滨和伊立替康方案治疗转移性结直肠癌的疗效和安全性。
Med Oncol. 2010 Sep;27(3):585-91. doi: 10.1007/s12032-009-9253-5. Epub 2009 Jun 13.
10
Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.西妥昔单抗联合卡培他滨和伊立替康对比西妥昔单抗联合卡培他滨和奥沙利铂作为转移性结直肠癌一线治疗：德国 AIO CRC 研究组的 AIO KRK-0104 随机试验。
J Clin Oncol. 2011 Mar 10;29(8):1050-8. doi: 10.1200/JCO.2010.31.1936. Epub 2011 Feb 7.

引用本文的文献

1
Efficacy and safety of triplet regimen capecitabine, oxaliplatin, and irinotecan (XELOXIRI) as first-line chemotherapy for advanced pancreatic cancer.卡培他滨、奥沙利铂和伊立替康三联方案（XELOXIRI）作为晚期胰腺癌一线化疗的疗效和安全性
BMC Cancer. 2025 Mar 12;25(1):449. doi: 10.1186/s12885-025-13799-5.
2
Trends in patterns of treatment and survival of colorectal cancer patients using cancer registry data in Japan: 1995-2015.日本癌症登记数据中结直肠癌患者治疗模式和生存趋势变化：1995-2015 年。
Cancer Sci. 2024 Aug;115(8):2786-2794. doi: 10.1111/cas.16210. Epub 2024 May 7.
3
Real-World Outcomes of First-Line FOLFIRI Plus Bevacizumab with Irinotecan Dose Escalation versus FOLFOXIRI Plus Bevacizumab in -Mutant Metastatic Colorectal Cancer: The Preliminary Data from a Single-Center Observational Study.
一线 FOLFIRI 联合贝伐珠单抗加伊立替康剂量递增与 FOLFOXIRI 联合贝伐珠单抗治疗 - 突变转移性结直肠癌的真实世界结局：来自单中心观察性研究的初步数据。
Medicina (Kaunas). 2023 Dec 1;59(12):2108. doi: 10.3390/medicina59122108.
4
Comparative Analysis of First-Line FOLFOX Treatment With and Without Anti-VEGF Therapy in Metastatic Colorectal Carcinoma: A Real-World Data Study.一线 FOLFOX 治疗联合与不联合抗 VEGF 治疗转移性结直肠癌的比较分析：一项真实世界数据研究。
Cancer Control. 2023 Jan-Dec;30:10732748231202470. doi: 10.1177/10732748231202470.
5
Clinical Outcomes of Patients with Peritoneal Metastasis-Only Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI Through Irinotecan Dose Escalation According to Polymorphism: Compared to Liver Metastasis-Only, and Lung Metastasis-Only.一线使用贝伐单抗和FOLFIRI方案并根据基因多态性调整伊立替康剂量治疗仅发生腹膜转移的结直肠癌患者的临床结局：与仅发生肝转移和仅发生肺转移的患者比较。
Cancer Manag Res. 2022 Apr 23;14:1541-1549. doi: 10.2147/CMAR.S355318. eCollection 2022.
6
Colorectal Cancer: From Genetic Landscape to Targeted Therapy.结直肠癌：从基因图谱到靶向治疗
J Oncol. 2021 Jul 6;2021:9918116. doi: 10.1155/2021/9918116. eCollection 2021.
7
Polymorphism for Irinotecan Dose Escalation in Patients with -Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI.一线使用贝伐单抗和FOLFIRI治疗的KRAS基因变异转移性结直肠癌患者伊立替康剂量递增的多态性
J Oncol. 2021 Mar 9;2021:6686517. doi: 10.1155/2021/6686517. eCollection 2021.
8
Colorectal Cancer (CRC) treatment and associated costs in the public sector compared to the private sector in Johannesburg, South Africa.南非约翰内斯堡公立医院与私立医院的结直肠癌（CRC）治疗及其相关费用比较。
BMC Health Serv Res. 2020 Apr 7;20(1):290. doi: 10.1186/s12913-020-05112-w.
9
Intravoxel Incoherent Motion of Colon Cancer Liver Metastases for the Assessment of Response to Antiangiogenic Treatment: Results from a Pilot Study.结肠癌肝转移瘤的体素内不相干运动用于评估抗血管生成治疗的反应：一项初步研究的结果。
Med Princ Pract. 2020;29(5):429-435. doi: 10.1159/000505814. Epub 2020 Jan 9.
10
The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials.维持治疗策略在转移性结直肠癌中的作用：一项随机临床试验的系统评价和网络荟萃分析。
JAMA Oncol. 2020 Mar 1;6(3):e194489. doi: 10.1001/jamaoncol.2019.4489. Epub 2020 Mar 12.